Screener
Relmada Therapeutics, Inc. RLMD Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Relmada Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed August 7, 2024. Open the filing →
- Filed
- Aug 7, 2024
- Fiscal quarter
- Q2 FY2024
- Calendar quarter
- Q2 2024
- Accession
- 0001213900-24-066111
FAQ
- What is Relmada Therapeutics, Inc.'s debt-to-equity?
- Relmada Therapeutics, Inc. (RLMD) reported debt-to-equity of 0.9× in Q2 2023.
- How has Relmada Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Relmada Therapeutics, Inc.'s debt-to-equity increased by 5.3% year-over-year, from 0.9× to 0.9×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Relmada Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude